Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD

+ acute myeloid leukemia
SUPPLEMENTARY MATERIALS Tumor evaluation
Body weight and tumor diameter were measured in xenografted nude mice xenografted with MV4-11 cells on the indicated days for each experimental group: 1. Gilteritinib plus AraC/DNR: Days −1, 3, 6, 9, 14, 17, and 21; 2. Gilteritinib plus AraC/IDR: Days 0, 3, 7, 10, 14, 17, and 21; 2, 5, 8, 12, 15, 19, and 21 . Body weight and tumor assessments obtained on Day −1 were designated as Day 0 (baseline) measurements. Tumor diameter was measured using a caliper and tumor volume was determined by calculating the volume of an ellipsoid (ie, Length × Width 2 × 0.5). The percent inhibition of tumor growth was calculated using the formula:
× (1 -[mean {(tumor volume of each mouse on the last day of observation) -(tumor volume of each mouse on Day 0]} of each group] / [mean {(tumor volume of each mouse on the last day of observation) -(tumor volume of each mouse on Day 0)} of the control group])
The percent tumor regression was calculated using the formula:
× (1 -[mean tumor volume of each group on the last day of observation] / [mean tumor volume of each group on Day 0])
Treatments for pharmacokinetic assays
For pharmacokinetic (PK) assays involving gilteritinib plus AraC and IDR, nude mice xenografted with MV4-11 cells received one of the following combination treatments: 1. Oral gilteritinib (3 mg/kg in 0.5% methylcellulose); 2. Oral methylcellulose (0.5%) in combination with IV IDR (0.5 mg/kg) and IP AraC (50 mg/kg); 3. Oral gilteritinib (3 mg/kg) plus IV IDR (0.5 mg/ kg) and IP AraC (50 mg/kg). For combination PK assays involving gilteritinib plus Aza, nude mice xenografted with MV4-11 received one of the following:
1. Oral gilteritinib (3 mg/kg) plus IV saline; 2. Oral methylcellulose (0.5%) plus IV Aza (3 mg/kg); 3. Oral gilteritinib (3 mg/kg) plus IV Aza (3 mg/kg).
